Special Issue: Payer/Provider Relationships in Oncology
It is not just 1 physician who cares for a patient enrolled onto a clinical trial but rather a complex system of several physician teams, sometimes with very different opinions, who must work together for therapy to be successful and for the patient to have faith in his treating team.
Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis
May 10th 2012Out-of-pocket payments differ widely among oral oncolytic options. As cost for therapy becomes a greater part of treatment decisions, an understanding of patient out-of-pocket cost will be critical in informing choices.
Effect of Insurance Status on the Stage of Breast and Colorectal Cancers in a Safety-Net Hospital
May 10th 2012In a safety-net hospital, patients with Medicaid have rates of advanced-stage cancer similar to those patients with other types of insurance; however, patients with no insurance have significantly higher rates of advanced disease.
US Payer Perspectives on Evidence for Formulary Decision Making
May 10th 2012To improve formulary design processes and support payers in providing more effective healthcare, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.
Treating ALK-Positive Lung Cancer in the Weeks After the FDA Approval of Crizotinib
May 10th 2012As physicians enter a new world of therapies for molecularly defined lung cancer, it will be critical for hospitals, drug companies, and insurance companies to work out the interplay of molecular testing and coverage for expensive therapies that are effective but only in smaller, defined groups of patients.
